

Yale University

EliScholar – A Digital Platform for Scholarly Publishing at Yale

Yale Day of Data

Day of Data 2016

Penetrance estimates for incidental genomic findings in ACMG-59

James A. Diao

Yale University, james.diao@yale.edu

Follow this and additional works at: <http://elischolar.library.yale.edu/dayofdata>



Part of the [Computational Biology Commons](#), [Diagnosis Commons](#), and the [Genomics Commons](#)

Diao, James A., "Penetrance estimates for incidental genomic findings in ACMG-59" (2017). *Yale Day of Data*. 10.
<http://elischolar.library.yale.edu/dayofdata/2016/posters/10>


This Event is brought to you for free and open access by EliScholar – A Digital Platform for Scholarly Publishing at Yale. It has been accepted for inclusion in Yale Day of Data by an authorized administrator of EliScholar – A Digital Platform for Scholarly Publishing at Yale. For more information, please contact elischolar@yale.edu.



Penetrance Estimates for Incidental Genomic Findings

James Diao, Arjun Manrai, Isaac Kohane

Division of Health Sciences and Technology, Harvard-MIT
Department of Biomedical Informatics, Harvard Medical School



INTRODUCTION


(Genetic Testing and Relevant Datasets)

Genetic testing: a difference from the reference genome (variant) may indicate disease.

Incidental finding: variant in gene unrelated to diagnostic indication that prompted sequencing.

-Due to multiple testing and low priors, these typically have *high rates of false positives*, so we normally don't report them.


ACMG (American College of Medical Genetics & Genomics): recommends an exception for 56 genes thought to be more indicative of disease.



1000 Genomes Project: contains whole-genome sequence data for 2,504 healthy adults from diverse ethnic populations.

ExAC: aggregates population-level data from 60,706 diverse human whole-genome sequences.

ClinVar: central repository of interpretations for genetic variants (benign vs. pathogenic).



OBJECTIVES

1. **Develop an ETL workflow** for extraction, transformation, and loading of genomic and interpretation data from relevant sources.
2. **Evaluate variant distribution** across a healthy, diverse cohort (1000 Genomes).
3. **Estimate plausible penetrance ranges** for the ACMG recommendations.

PENETRANCE MODEL

$$\text{Penetrance} = P(D|V) = \frac{P(D) * P(V|D)}{P(V)} = \frac{(\text{prevalence})(\text{allelic heterogeneity})}{(\text{allele frequency})}$$

where D = disease, V = any variant


- Penetrance:** Probability of developing disease, given a positive genetic test result.
- Prevalence:** Proportion of general population with disease.
- Allelic Heterogeneity:** Proportion of diseased population with a pathogenic variant.
- Allele Frequency:** Proportion of general population with a pathogenic variant.

METHODS & WORKFLOW

ETL for Datasets

Pipeline + UI using R/Shiny/Markdown


1. **Extract:** query UCSC Genome Browser for gene regions and retrieve corresponding VCF files from 1000 Genomes. Download ExAC manually from gene-level searches.
2. **Transform:** separate variants with multiple alternates; convert genotypes to allele counts, collect missense variants.
3. **Load:** Stage and merge final data objects.



<https://github.com/jamesdiao/2016-paper-ACMG-penetrance>

KEY FIGURES

Heatmap + Barplot: Penetrance Estimates are Low and Variable between Ancestral Groups



CONCLUSIONS

1. **High counts: 40-80%** of individuals have an incidental finding under ACMG guidelines, far higher than empirical disease prevalences.
2. **Clustered distribution:** by ethnicity – **AFR (African)** have the most findings, **EAS (East Asian)** have the fewest.
3. **High sensitivity:** findings dominated by a few high-frequency variants.
4. **Very low penetrance estimates:** Out of the 30 diseases (22 with data):
 - (a) 20 have max theoretical penetrance < 50%
 - (b) 12 have max theoretical penetrance < 5%
5. **High uncertainty around parameters:** translates into very large errors bars.

-This is a preliminary "letter-of-the-law" evaluation and does *not* yet demonstrate real-world effects on patients.

NEXT STEPS

1. **Identify questionable variants:**
 - (a) high-frequency (common findings)
 - (b) highly enriched in 1 ethnic population.
2. **Validation** with empirical penetrance values and other sequencing datasets (e.g. gnomAD).
3. **Model biases** in parameter estimates (prevalence, pathogenicity, etc.)
4. **Confer with clinical collaborators** to determine alternate protocols at Laboratory of Molecular Medicine and Partners HealthCare.

ACKNOWLEDGEMENTS

Raj: for his mentorship throughout this project.
Zak: for looking over & shaping my presentations.
HST Summer Institute Administration - (Susanne, Barbara, Dominique, Jean, and Sonal): for making everything possible.
DBMI: for all the AC and coffee.